Lixte Biotechnology Holdings Inc. has announced changes to its Board of Directors, with Jason Sawyer and Dr. Michael Holloway appointed as new independent members. This follows the resignation of Dr. Stephen Forman and Dr. Yun Yen, who have joined the company's Scientific Advisory Committee. Additionally, Dr. Jan Schellens will be stepping down as the Chief Medical Officer, effective July 31, 2025, to pursue other opportunities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-020408), on July 21, 2025, and is solely responsible for the information contained therein.